COST-EFFECTIVENESS OF DENOSUMAB IN PREVENTING OSTEOPOROTIC FRACTURES IN POSTMENOPAUSAL WOMEN FROM THE PRIVATE HEALTH CARE SETTING PERSPECTIVE IN BRAZIL

被引：1
|
作者：
Barbosa, E. G. [1 ]
Machado, M. [1 ]
Araujo, G. T. B. D. [2 ]
Etto, H. [2 ]
Fonseca, M. [3 ]
Olimpio, A. [1 ]
机构：
[1] GlaxoSmithKline Ltda, Rio De Janeiro, Brazil
[2] Axia Bio, Sao Paulo, Brazil
[3] Fed Univ Sao Paulo Axia Bio Consulting, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1396
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A446 / A447
页数：2
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF BISPHOSPHONATES IN THE PREVENTION OF FRACTURES IN OSTEOPENIC POSTMENOPAUSAL WOMEN IN COLOMBIA
    Diaz-Puentes, M.
    Rosselli, D.
    Colon-Pena, C. -A.
    [J]. AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (SUPPL 1) : S138 - S139
  • [32] COST-EFFECTIVENESS OF ZOLEDRONIC ACID ONCE-YEARLY INFUSION IN THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROTIC FRACTURES BASED ON COMPLIANCE AND NUMBER NEEDED TO TREAT APPROACH IN THE TURKISH HEALTH CARE SETTING
    Pala, M.
    Gol, D.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A439 - A440
  • [33] Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women
    J. A. Kanis
    F. Borgstrom
    O. Johnell
    B. Jonsson
    [J]. Osteoporosis International, 2004, 15 : 862 - 871
  • [34] Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women
    Kanis, JA
    Borgstrom, F
    Johnell, O
    Jonsson, B
    [J]. OSTEOPOROSIS INTERNATIONAL, 2004, 15 (11) : 862 - 871
  • [35] The cost-effectiveness of calcium and Vitamin D or hormone replacement therapy in the prevention of osteoporotic fractures in Canadian postmenopausal women.
    Papadimitropoulos, E.
    Goeree, R.
    Blackhouse, G.
    Coyte, P. C.
    Josse, R. G.
    Adachi, J. D.
    Greenwood, C. E.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S279 - S279
  • [36] The cost-effectiveness of calcium and vitamin D or hormone replacement therapy in the prevention of osteoporosis and osteoporotic fractures in Canadian postmenopausal women
    Papadimitropoulos, EA
    Blackhouse, G
    Goeree, R
    Coyte, PC
    Josse, RG
    Adachi, JD
    Greenwood, CE
    [J]. OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S84 - S85
  • [37] Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China
    You, Ruxu
    Mori, Takahiro
    Ke, Lei
    Wan, Yuansheng
    Zhang, Yu
    Luo, Fei
    Feng, Da
    Yu, Guangyi
    Liu, Jinyu
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2022, 29 (02): : 210 - 218
  • [38] Needs and cost-effectiveness in health care priority setting
    Gustavsson, Erik
    Tinghog, Gustav
    [J]. HEALTH AND TECHNOLOGY, 2020, 10 (03) : 611 - 619
  • [39] Needs and cost-effectiveness in health care priority setting
    Erik Gustavsson
    Gustav Tinghög
    [J]. Health and Technology, 2020, 10 : 611 - 619
  • [40] Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan
    Takahiro Mori
    Carolyn J. Crandall
    Tomoko Fujii
    David A. Ganz
    [J]. Archives of Osteoporosis, 2021, 16
12345